Based on preclinical data, we conducted a proof-of-concept phase Ia/Ib/IIa clinical study of GDC-0810 in women who were postmenopausal and with locally advanced or metastatic ER + (HER2 −) breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.